CJC-1295 for Fat Loss

What CJC-1295 is

CJC-1295 is a lab-made GHRH analog, a modified copy of the hormone that signals the pituitary to release growth hormone (GH). Lifters use it because GH promotes lipolysis, the breakdown of stored fat. The original form, CJC-1295 with DAC (drug affinity complex), binds to albumin in the blood and lasts for days. The form without DAC, usually sold as Mod GRF 1-29, is shorter-acting, but no published human study has measured its half-life. Every human trial used the DAC form.

What the human studies show

Two small 2006 trials in healthy adults hold nearly all the evidence. In Teichman's trial, one subcutaneous injection raised mean GH 2- to 10-fold for at least 6 days and IGF-1 1.5- to 3-fold for 9-11 days.

Ionescu and Frohman sampled GH every 20 minutes overnight in healthy men a week after one dose. GH still came in pulses of unchanged frequency and size. What rose was the level between pulses (trough GH up 7.5-fold), lifting mean GH by 46%. That contradicts the forum claim, repeated on this page until now, that the DAC form swaps natural pulses for a constant "GH bleed".

Neither trial measured body fat. As of October 2026, no study has tested CJC-1295 for fat loss, and FDA's December 2024 review found no human effectiveness data for any use. We rate the evidence as moderate: limited human data, all of it on hormone levels.

Fat loss: theory versus data

GH does mobilize fat, but raising it with a secretagogue hasn't reliably changed body composition. In a 2-year trial of 65 healthy older adults, oral MK-677 raised GH and IGF-1 to young-adult levels without reducing visceral or total fat. Fasting glucose rose while insulin sensitivity fell. MK-677 is a different compound, but this cuts against claims that CJC-1295 improves insulin sensitivity or targets belly fat. Our article on long-term health effects of peptide use covers the glucose concern.

How users describe using it

These doses are reported, not recommended. Most forum users describe the no-DAC form at 100-300 mcg per subcutaneous injection, often at bedtime on an empty stomach with ipamorelin. No trial has tested that pairing; see our ipamorelin fat-loss article.

Vendor and community guides list 500-1,000 mcg per week of the DAC form, a range we couldn't trace to a trial. The 2006 trials dosed by body weight (30-250 mcg/kg), with 30-60 mcg/kg best tolerated.

Some users add HGH fragment 176-191, though its relative AOD-9604 mostly failed to beat placebo in oral human weight-loss trials, per FDA's 2024 review.

Side effects and safety signals

FDA's 2024 summary of the trials found:

• Adverse events in 94% of first-trial participants after one injection, including injection-site reactions in about 70%
• Headache and diarrhea, plus vasodilatory reactions such as flushing
• Dizziness and low blood pressure in the second trial, along with brief involuntary leg contractions
• Raised heart rate in the Ionescu and Frohman study
• IGF-1 above the normal range at the top dose of 250 mcg/kg

A Phase 2 trial in people with HIV lipodystrophy was stopped after a participant had a fatal heart attack 2 hours after their 11th weekly dose. The physician blamed undiagnosed coronary artery disease. The data were never published.

Users most often report flushing and water retention. Numb or tingling hands come up too. Some describe tiredness or poor sleep.

Legal and sport status

As of October 2026, CJC-1295 isn't approved as a medicine anywhere. FDA's compounding advisers voted in December 2024 against letting US pharmacies compound it, and FDA's safety-risk list cites raised heart rate and systemic vasodilatory reactions. WADA's 2026 Prohibited List names it under S2.2.4, banning it at all times for tested athletes (see peptide rules in sport).

What we still don't know

Nobody knows whether CJC-1295 reduces body fat in people, or what months of use do to glucose control.